IndustryCompany release

Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient

🇺🇸 Xenetic Biosciences, Inc. (XBIO) · Fri 13 Nov 2026

The US biotech posted about $0.7m in royalty revenue and $5.8m in cash, and plans a Q1 2027 close for its Santersus acquisition.

Xenetic Biosciences reported third-quarter 2026 results on 13 November, with royalty revenue of about $0.7 million, a net loss of about $1.7 million and cash of about $5.8 million.

The company also detailed a definitive share exchange agreement to acquire Santersus AG in an all-stock transaction. Completion is expected in the first quarter of 2027, subject to stockholder approval and Nasdaq listing of the new shares to be issued.

If the deal closes, the combined company would focus on targeting neutrophil extracellular traps. Its sepsis and lupus programmes hold FDA Breakthrough Device Designations. As general context, this designation is intended to speed development and review of devices for serious conditions, but it does not equal marketing authorisation.

Xenetic also said an investigator-led Phase I study combining DNase I with anti-CD19 CAR T-cell therapy in large B-cell lymphoma has dosed its first patient. Initial efficacy data are expected in the second quarter of 2027.

What it means for your team

  • Closing of the Santersus transaction depends on stockholder approval and Nasdaq listing of the new shares, so the Q1 2027 timeline is not guaranteed.
  • Teams tracking device-based sepsis or lupus approaches should note the FDA Breakthrough Device Designations held by the Santersus-linked programmes.
  • The DNase I plus CAR-T study is early-stage and investigator-led; first efficacy readout is not expected until Q2 2027.

Company's press release (SEC filing): Xenetic Biosciences, Inc. ↗

Article written by VigiEye from the official source (Xenetic Biosciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →